Celltrion Secures Additional FDA Approval for Yuflyma 10mg Formulation in US
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
Celltrion has received FDA approval for additional pediatric indications of Yuflyma in the US, targeting pediatric uveitis and hidradenitis suppurativa, and aims to expand its market presence as exclusivity for the original drug expires.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #PediatricIndications #Adalimumab #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=86225
Celltrion Secures Additional Pediatric Indications for Yuflyma in US
Celltrion has received FDA approval for additional pediatric indications of Yuflyma in the US, targeting pediatric uveitis and hidradenitis suppurativa, and aims to expand its market presence as exclusivity for the original drug expires.
Celltrion - 'Yuflyma Achieves Interchangeable Status with Humira in U.S.'
Celltrion's Yuflyma gains FDA approval for interchangeability with Humira, boosting its competitive edge in the lucrative U.S. autoimmune disease treatment market
Yonhap Infomax News